Edward Rosfjord

TL;DR: HKI-272 is a potent inhibitor ofHER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro and in vivo, and has been selected as a candidate for additional development as an antitumor agent in breast and other HER- 2-dependent cancers.

TL;DR: A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared and one compound, 5, which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clinical trials for the treatment of cancer.

TL;DR: Progress made in the development of PDX models in key areas of oncology research are reviewed, including target identification and validation, tumor indication search and thedevelopment of a biomarker hypothesis that can be tested in the clinic to identify patients that will benefit most from therapeutic intervention.

TL;DR: The authors demonstrated the effectiveness of this therapy in mouse models of several tumor types and confirmed that it reduces tumor-initiating cells and outperforms standard chemotherapy, and also had some unexpected benefits, reducing tumor angiogenesis and promoting antitumor immunity.

TL;DR: A complexdynamic pattern of cell death-inducing and survivalfactors that promote the development of the maturemammary gland and that rapidly remodel the tissue afterlactation is described.